HomepageSGEN • BMV
add
Seagen
Vorige slotkoers
$Â 3.711,48
Jaar-range
$Â 3.711,48 - $Â 3.711,48
Beurswaarde
43,15Â mld. USD
Koers/winst
-
Dividendrendement
-
Marktnieuws
.INX
0,40%
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(USD) | sep 2023info | Wijziging j-o-j |
---|---|---|
Opbrengst | 648,65Â mln. | 27,11% |
Bedrijfskosten | 262,69Â mln. | 24,86% |
Netto inkomsten | -215,79Â mln. | -13,09% |
Netto winstmarge | -33,27 | 11,02% |
Winst per aandeel | -1,15 | -11,65% |
EBITDA | -209,33Â mln. | -19,47% |
Effectief belastingtarief | 0,26% | — |
Balans
Totale activa
Totale passiva
(USD) | sep 2023info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 1,24Â mld. | -29,86% |
Totale activa | 3,63Â mld. | 0,42% |
Totale passiva | 1,08Â mld. | 35,94% |
Totaal aandelenvermogen | 2,55 mld. | — |
Uitstaande aandelen | 188,66 mln. | — |
Koers-boekwaardeverhouding | 274,52 | — |
Rendement op activa | -16,01% | — |
Rendement op kapitaal | -21,12% | — |
Kasstroom
Nettomutatie in liquide middelen
(USD) | sep 2023info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -215,79Â mln. | -13,09% |
Operationele kasstroom | -35,82Â mln. | 58,21% |
Kasstroom uit beleggingen | 142,49Â mln. | 119,31% |
Kasstroom uit financiering | 15,52Â mln. | -15,59% |
Nettomutatie in liquide middelen | 119,90Â mln. | 1.958,05% |
Vrije kasstroom | 71,52Â mln. | 1.141,10% |
Over
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The company's flagship product Adcetris is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program
to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Wikipedia
Opgericht
15 jul 1997
Hoofdvestiging
Website
Werknemers
3.256